A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia

Journal of Clinical Psychiatry

Volumn 65, Issue 5, 2004, Pages 696-701

  Emsley, Robin ^a   Turner, H Jadri ^a   Schronen, Juan ^a   Botha, Karien ^a   Smit, Retha ^a   Oosthuizen, Piet P ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DIBENZOTHIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; QUETIAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DYSKINESIA; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 2942731496     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0516     Document Type: Article

References (38)

1. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(4 suppl):52S-56S (Pubitemid 18214346)
2. Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis treated with low-dose haloperidol. J Clin Psychiatry 2003;64:1075-1080 (Pubitemid 37158253)
3. Hansen TE, Brown WL, Weigel RM, et al. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry 1992;14:340-344
4. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
5. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609 (Pubitemid 27485969)
6. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41:1030-1035 (Pubitemid 14017412)
7. Dixon L, Thaker G, Conley RR, et al. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Bull 1993;10:267-271 (Pubitemid 23353442)
8. McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2000; CD000459
9. Jeste DV, Potkin SG, Sinha S, et al. Tardive dyskinesia: reversible and persistent. Arch Gen Psychiatry 1979;36:585-590 (Pubitemid 9201191)
10. American Psychiatric Association Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Press; 1992
11. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(suppl B):102-106 (Pubitemid 24353029)
12. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-322 (Pubitemid 27362488)
13. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160:1117-1124 (Pubitemid 41070971)
14. Umbrich P, Soares KV. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2003; CD000205
15. Tammenmaa IA, McGrath JJ, Sailas E, et al. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2002; CD000207
16. Soares KV, McGrath JJ, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001; CD000203
17. Nelson LA, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother 2003;37:1128-1131 (Pubitemid 36875249)
18. Soares KV, McGrath JJ. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;CD000206
19. McGrath JJ, Soares KV. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000;CD000208
20. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol 1995;15:36S-44S
21. Arvanitis LA, Miller BG, for the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
22. Glazer WM, Morgenstern H, Pultz JA. Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses. Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco, Mexico
23. Jeste DV, Glazer WM, Morgenstern H. Rarity of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco, Mexico
24. Tauscher J, Kufferle B, Asenbaum S, et al. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with haloperidol and placebo. Psychopharmacology (Berl) 2002;162:42-49 (Pubitemid 34639555)
25. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-884
26. Xu H, Qing H, Lu W, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002;321:65-68 (Pubitemid 34185500)
27. Goldstein JM. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwan GW, eds. Schizophrenia: Breaking Down the Barriers. Chichester, England: John Wiley & Sons; 1996:177-236
28. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982;39:486-487
29. International Conference on Harmonization. ICH Harmonised Tripartite Guidelines for Good Clinical Practice. Surrey, England: Brookwood Medical Publications Ltd; 1996
30. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233
31. Kay SR, Fizbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-267
32. Mallinckrodt CH, Sanger T, Dube S, et al. Assessing and interpreting effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003;53:754-760 (Pubitemid 39658489)
33. Vesely C, Kufferle B, Brucke T, et al. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 2000;15:57-60 (Pubitemid 30058142)
34. Farah A. Reduction of tardive dyskinesia with quetiapine [letter]. Schizophr Res 2001;47:309-310 (Pubitemid 32244116)
35. Alptekin K, Kivircik BB. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. Int Clin Psychopharmacol 2002;17:263-264
36. Emsley RA, Raniwalla J, Bailey PJ, et al, for the PRIZE Study Group. A comparison of the effects of quetiapine ("Seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000;15:121-131
37. Wahlbeck K, Tuunainen A, Ahokas A, et al. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001;155:230-233 (Pubitemid 32477278)
38. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000;61(suppl 4):39-44 (Pubitemid 30158602)